Physician profile
Maureen Quinlan
NPI 1003013632
$45,853.48
in general payments reported to CMS, 2019-2025
25 companies · $69.96 in 2025
The $69.96 reported for 2025 was less than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $318 · 2021: $126 · 2022: $95.49 · 2023: $126 · 2024: $45K · 2025: $69.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $45K · Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $44,800.00 |
| Food and Beverage | $362.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $44,800.00 | 2024 | |
| Musculoskeletal Transplant Foundation INC. | $287.60 | 2019-2021 | |
| Nevro Corp. | $118.62 | 2022-2024 | Senza |
| Paratek Pharmaceuticals, INC. | $115.84 | 2022-2025 | Nuzyra |
| Smith+Nephew, INC. | $101.11 | 2019-2024 | Grafix Pl, Stravix, Regranex |
| Abbvie INC. | $40.75 | 2023 | |
| Melinta Therapeutics, LLC | $34.03 | 2019-2021 | |
| Cashflow Solutions, LLC | $30.68 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Sebela Pharmaceuticals INC. | $30.22 | 2019-2020 | |
| Grt US Holding, INC. | $29.89 | 2021 | |
| Merck Sharp & Dohme LLC | $28.35 | 2019 | |
| Stryker Corporation | $25.52 | 2022 | |
| Nabriva Therapeutics, Plc | $25.17 | 2020-2022 | |
| Integra Lifesciences Corporation | $22.00 | 2021 | |
| Kerecis Limited | $21.61 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ermi LLC | $18.47 | 2020 | |
| Abbott Laboratories | $16.73 | 2023 | Proclaim |
| Triad Life Sciences INC. | $16.40 | 2022 | |
| Wright Medical Technology, INC. | $16.25 | 2020 | |
| Zyla Life Sciences, INC. | $13.71 | 2020 | |
| Horizon Therapeutics Plc | $13.68 | 2019 | |
| Novum Pharma, LLC | $13.49 | 2019 | |
| Paragon 28, INC. | $11.43 | 2019 | |
| Zimmer Biomet Holdings, INC. | $11.05 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Quinlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.